Advanced Health Intelligence Ltd. announced that the Company has entered into a Collaboration Agreement with UAE-Based IntelliGen FZ-LLC to deploy the AHI technology throughout the Middle East. The Collaboration Agreement between AHI and IntelliGen represents the successful conclusion of an extensive evaluation process by IntelliGen, which encompassed technology functionality, usability, and health evaluation. The collaboration between AHI and IntelliGen represents a ground-breaking initiative to address the pressing healthcare challenges in the Middle East, particularly in Saudi Arabia.

This partnership combines AHI?s advanced technology with IntelliGen?s deep understanding of in-country needs and its founders? extensive experience in healthcare provision and government collaboration. At the heart of this collaboration is the purpose-focused digital health platform designed to tackle the nation?s high rates of chronic disease.

The platform?s primary goal is to shift the healthcare paradigm from reactive to proactive, focusing on early identification and intervention of chronic diseases rather than episodic care when the problem has already manifested. It is widely recognised that the region has high rates of chronic diseases. For instance, the World Health Organization (WHO) has reported that non-communicable diseases (NCDs), which include chronic diseases like heart disease, stroke, cancer, diabetes, and chronic lung disease, account for 74% of global deaths and 58% of deaths in the Eastern Mediterranean region, which includes most Middle Eastern countries.

Specifically, the prevalence of diabetes is exceptionally high. According to the International Diabetes Federation, in 2019, approximately 55 million adults in the Middle East and North Africa region (MENA) had diabetes, representing a prevalence rate of around 12.2% among adults, which is one of the highest rates globally.